This announcement contains inside information as stipulated under the
EDX Medical Group Plc
EDX Medical Group plc (“EDX Medical” or the “Company”), which develops innovative digital diagnostic products and services for cancer, heart disease, neurology and infectious disease testing, today announces that Jason Holt, Non-executive Chairman of the Company, purchased 400,000 ordinary shares in the Company at an aggregate price of
The directors of the Company accept responsibility for the contents of this announcement.
For more information, please contact:
EDX Medical PLC
Tel: 020 7220 9795
Media House International,
Tel: +44 (0) 7788 414856:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|1||Details of the person discharging managerial responsibilities / person closely associated|
|2||Reason for the notification|
|b)||Initial notification /Amendment||Initial notification|
|3||Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor|
|a)||Name||EDX Medical Group Plc|
|4||Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted|
|a)||Description of the financial instrument, type of instrument
|Ordinary shares of
Identification code (ISIN) for EDX Medical Group Plc ordinary shares: GB00BNDMJS47
|b)||Nature of the transaction||Purchase of Ordinary Shares|
|c)||Price(s) and volume(s)||
- Aggregated volume
|e)||Date of the transaction||10 March 2023|
|f)||Place of the transaction||AQSE Growth Market|
Notes for Editors:
About EDX Medical Group
EDX Medical develops and delivers innovative digital diagnostic products and services for cancer, heart disease, neurology and infectious disease testing, helping to predict disease risk, inform clinical decision-making and accelerate the development of new medicines. The company is listed on the Access Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience in the sector, specialising in cancer treatments and diagnostics.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection of disease risk and personalise disease management in a timely fashion. Early disease detection and risk prediction is the most impactful way of reducing deaths and lowering the future costs of healthcare provision globally.
EDX Medical operates a molecular biology and diagnostics laboratory in